| __timestamp | Halozyme Therapeutics, Inc. | ImmunityBio, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 35942000 | 4326000 |
| Thursday, January 1, 2015 | 40028000 | 226206000 |
| Friday, January 1, 2016 | 45853000 | 94391000 |
| Sunday, January 1, 2017 | 53816000 | 53821000 |
| Monday, January 1, 2018 | 60804000 | 35463000 |
| Tuesday, January 1, 2019 | 77252000 | 46456000 |
| Wednesday, January 1, 2020 | 45736000 | 71318000 |
| Friday, January 1, 2021 | 50323000 | 135256000 |
| Saturday, January 1, 2022 | 143526000 | 102708000 |
| Sunday, January 1, 2023 | 149182000 | 129620000 |
| Monday, January 1, 2024 | 154335000 |
Data in motion
In the competitive landscape of biotechnology, managing operational costs is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Halozyme Therapeutics, Inc. and ImmunityBio, Inc. over the past decade. From 2014 to 2023, Halozyme's SG&A expenses have shown a steady increase, peaking in 2023 with a 315% rise from 2014. ImmunityBio, on the other hand, experienced a more volatile trajectory, with a significant spike in 2015, marking a 5,130% increase from the previous year. By 2023, ImmunityBio's expenses had stabilized, showing a 2,895% increase from 2014. This data highlights the strategic financial management of these companies, reflecting their growth and adaptation in the biotech sector. Understanding these trends provides valuable insights into their operational strategies and market positioning.
Comparing SG&A Expenses: Eli Lilly and Company vs Halozyme Therapeutics, Inc. Trends and Insights
Breaking Down SG&A Expenses: AbbVie Inc. vs Halozyme Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Amgen Inc. and ImmunityBio, Inc.
SG&A Efficiency Analysis: Comparing BioMarin Pharmaceutical Inc. and ImmunityBio, Inc.
Comparing SG&A Expenses: Catalent, Inc. vs ImmunityBio, Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing Halozyme Therapeutics, Inc. and Rhythm Pharmaceuticals, Inc.
R&D Insights: How Halozyme Therapeutics, Inc. and ImmunityBio, Inc. Allocate Funds
Operational Costs Compared: SG&A Analysis of Halozyme Therapeutics, Inc. and Iovance Biotherapeutics, Inc.
Who Optimizes SG&A Costs Better? Halozyme Therapeutics, Inc. or Taro Pharmaceutical Industries Ltd.
Comparing SG&A Expenses: ImmunityBio, Inc. vs MannKind Corporation Trends and Insights
SG&A Efficiency Analysis: Comparing ImmunityBio, Inc. and Taro Pharmaceutical Industries Ltd.
Breaking Down SG&A Expenses: ImmunityBio, Inc. vs Travere Therapeutics, Inc.